Incyte | INCY - Ebitda

Aktienkurs
95.59
Täglich Wechseln
0.40 0.42%
Monatlich
-1.37%
Jährlich
46.39%
Q2 Prognose
93.39




Ebitda Veränderung Datum
Acadia Pharmaceuticals USD 20.31M 15.44M 2025-12
Agenus USD -10.11M 19.02M 2025-03
Agios Pharmaceuticals USD -120.31M 4.82M 2025-12
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amgen USD 5.14B 775M 2025-12
BioCryst Pharmaceuticals USD 51.7M 30.14M 2025-09
Biogen USD 649.7M 76.5M 2026-03
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Bristol-Myers Squibb USD 2.88B 1.36B 2025-12
Eli Lilly USD 12.14B 4.26B 2025-12
Exelixis USD 258.29M 15.43M 2026-03
Gilead Sciences USD 3.02B 1.01B 2025-12
Incyte USD 367.97M 46.53M 2026-03
Ionis Pharmaceuticals USD -200.02M 42.89M 2025-12
MacroGenics USD 21.95M 55.39M 2025-09
Merck USD 6.3B 2.09B 2025-12
Moderna USD -790M 582M 2025-12
Nektar Therapeutics USD -31.81M 70K 2023-09
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Novartis USD 5.3B 530M 2026-03
Novartis USD 5.84B 235M 2025-09
Pfizer USD 5.99B 5.23B 2026-03
PTC Therapeutics USD -70.99M 91.62M 2025-12
Puma Biotechnology USD 729K 11.36M 2024-06
Regeneron Pharmaceuticals USD 1.2B 718.4M 2025-12
Sarepta Therapeutics USD -252.2M 84.16M 2025-12
Ultragenyx Pharmaceutical USD -99.43M 57.35M 2025-12
Vertex Pharmaceuticals USD 1.19B 195.3M 2026-03